Emergex gains new R&D facility and CSO by Angus Liu Wednesday, February 20, 2019 The company aims to enter the clinic with a pan-flavivirus vaccine against Zika, dengue and yellow fever in 2019.
Emergent and Valneva's Zika vaccine clears phase 1 by Angus Liu Tuesday, November 20, 2018 A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results.
J&J opens €72M vaccine plant for stepped-up R&D by Eric Sagonowsky Thursday, October 25, 2018 Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.
Scientists weigh Zika challenge study: report by Eric Sagonowsky Tuesday, September 18, 2018 Zika vaccine research continues in the absence of a large-scale outbreak, but a shortage of cases is making it hard to test for efficacy.
Zika, VBI Vaccines and more—News of Note by Eric Sagonowsky Tuesday, August 21, 2018 Here is some other vaccine news of note for the week.
3. Sanofi by Angus Liu By the numbers, Sanofi’s vaccines business did quite well in 2017. Revenue grew an impressive 8.3% to reach €5.1 billion ($6.12 billion). But beyond the income statement, last year wasn’t without headline-hogging controversies and setbacks.
Platform tech bringing 'major switch' to vaccine R&D by Eric Sagonowsky Wednesday, March 28, 2018 Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.
Novavax talks up $1.5B sales target in RSV by Eric Sagonowsky Wednesday, March 21, 2018 Novavax may be years away from a potential approval of its RSV vaccine, but executives aren't waiting to prepare for a possible rollout.
Sanofi, flu vaccines and more—News of Note by Angus Liu Wednesday, February 28, 2018 Here's some other vaccine news of note for the week.
